1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds
  5. FDA Grand Rounds – Clinical Omics Biomarker Discovery and Validation in Precision Medicine Applications - 04/09/2026
  1. FDA Grand Rounds

Webcast | Virtual

Event Title
FDA Grand Rounds – Clinical Omics Biomarker Discovery and Validation in Precision Medicine Applications
April 9, 2026

Date:
April 9, 2026
Time:
12:00 p.m. - 1:00 p.m. ET

Webcast Recording

For technical assistance please contact: Rakesh.Raghuwanshi@fda.hhs.gov

Speaker

Richard Beger, Ph.D.


Richard Beger, Ph.D. 
Branch Chief
Division of Systems Biology
National Center for Toxicological Research
Office of the Chief Scientist
U.S. Food and Drug Administration

About the Speaker

Dr. Beger received his Ph.D. in biophysics from Purdue University in 1991 and completed postdoctoral training in nuclear magnetic resonance at Wesleyan University and Johns Hopkins University School of Medicine before joining NCTR’s Division of Chemistry in 1998. He is currently the Branch Chief of the Omics, Modeling, Imaging and Chemistry (OMIC) Branch in the Division of Systems Biology, a diverse group of scientists working in the fields of metabolomics, proteomics, tissue imaging, and chemical modeling of toxicological and disease endpoints. Dr. Beger has been involved with metabolomics data quality since 2015 and was part of a group of scientists that started the metabolomics quality assurance and quality control consortium (mQACC) in 2018 He was on the coordinating committee of mQAAC from 2019-2022, including the chair of mQACC in 2022. Dr. Beger won the 2016 Society of Toxicology translational impact award for developing translational approaches to improve drug safety, disease detection/management, and human health. He has authored more than 190 published manuscripts including over 70 manuscripts in metabolomics, over 20 manuscripts in chemical activity modeling, over 10 manuscripts in proteomics, and systems biology and personalized medicine, 14 employee invention reports, and six patents.

About the Presentation

This lecture will provide an overview of Systems Biology omics and biomarker concepts with four examples of omics analyses of human blood samples. The examples include metabolomics and miRNA analysis of serum during acetaminophen-induced liver toxicity, proteomic analysis of serum to predict kidney recovery from dialysis, baseline proteomics analysis of blood from patients receiving doxorubicin treatment, and method for discovery and validation of miRNA-proteins pairs in plasma associated with respiratory disease.

Back to Top